Clinical trials: Pulmonary Artery Sarcoma
Pulmonary Artery Sarcoma
Study for the Clinical Roadmap and Prognosis of Pulmonary Artery Sarcoma.
This is an observational study in which patients with pulmonary artery sarcoma were followed up for at least 36 months and survival was investigated.
- Trial name
- NCT06165718
- Where
- China
- Volunteers
- 120 people
- Sponsor
- China-Japan Friendship Hospital
Metastases, Neoplasm, Colorectal Neoplasms
Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver
MTC-DOX is Doxorubicin or DOX, a chemotherapy drug, that is adsorbed, or made to "stick", to magnetic beads (MTCs). MTCs are tiny, microscopic particles of iron and carbon.
- Conditions
- Metastases, Neoplasm, Colorectal Neoplasms, Esophageal Neoplasms, Stomach Neoplasms
- Trial name
- NCT00041808
- Testing
- MTC-DOX for Injection, Chemotherapy
- Where
- 4 sites in United States, Germany
- Volunteers
- 20 people
- Sponsor
- FeRx
Chronic Thromboembolic Pulmonary Hypertension (CTEPH), Acute Pulmonary Embolism (PE)
Large Language Model Support for CTEPH Differential Diagnosis
This randomized controlled trial aims to evaluate whether a locked large language model (LLM)-based clinical decision support system improves the differential diagnosis of pulmonary artery filling defects among physicians who do…
- Conditions
- Chronic Thromboembolic Pulmonary Hypertension (CTEPH), Acute Pulmonary Embolism (PE), Pulmonary Artery Sarcoma
- Trial name
- NCT07902011
- Testing
- Locked CTEPH-LLM Diagnostic Decision Support
- Where
- China
- Volunteers
- 60 people
- Sponsor
- China-Japan Friendship Hospital
Lung Cancer, Liver Cancer
Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
This trial is designed to investigate the safety, response rates and survival outcomes of patients with advanced solid tumors by infusion of CTLA4, PD1 and PDL1 antibodies combination through venous (IV), artery (IA) or…
- Conditions
- Lung Cancer, Liver Cancer, Colorectal Cancer, Pancreas Cancer
- Trial name
- NCT05187338
- Testing
- ipilimumab +pembrolizumab +durvalumab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University